Andrea Cercek
安德里亚·切尔切克
MD
Attending Physician, GI Oncology; Co-Director, Center for Young Onset Colorectal Cancer消化系统肿瘤内科主治医师；年轻发病结直肠癌中心联席主任
👥Biography 个人简介
Dr. Andrea Cercek is a GI oncologist at MSKCC whose landmark 2022 study showed that dostarlimab alone achieved 100% clinical complete response in locally advanced MSI-H rectal cancer, potentially sparing patients surgery and radiation. She also leads research in early-onset colorectal cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Dostarlimab Organ Preservation in Rectal Cancer
Led the groundbreaking trial demonstrating 100% clinical complete response with PD-1 blockade in MSI-H locally advanced rectal cancer, challenging the need for standard chemoradiation.
Early-Onset Colorectal Cancer
Co-directs MSKCC's program investigating rising incidence, unique biology, and treatment of colorectal cancer in patients under 50.
Representative Works 代表性著作
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer
New England Journal of Medicine (2022)
Landmark study: 12/12 patients with MSI-H rectal cancer achieved complete clinical response on dostarlimab alone, with none requiring surgery.
Distinct clinical and molecular features of early-onset colorectal cancer
Journal of Clinical Oncology (2021)
Characterized the clinical and genomic landscape of early-onset CRC at MSKCC, highlighting distinct molecular subtypes in young patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 安德里亚·切尔切克 的研究动态
Follow Andrea Cercek's research updates
留下邮箱，当我们发布与 Andrea Cercek（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment